AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, diagnostic and interventional guidewires, and coaxial micro-introducer kits for use in peripheral diagnostic and interventional procedures. In addition, the company provides abscession drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-access kits offer interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $292M | $2M | $-34M | $-15M | -18.6% | -3.8% | - |
| 2024 | $304M | $-6M | $-184M | $-34M | -89.7% | -10.3% | - |
| 2023 | $339M | $12M | $-52M | $-4M | -13.9% | 7.1% | - |
| 2022 | $316M | $11M | $-27M | $-11M | -6.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 316.22 | 338.75 | 303.91 | 292.50 |
| Cost Of Revenue | 150.49 | 164.51 | 149.22 | 134.79 |
| Gross Profit | 165.73 | 174.25 | 154.70 | 157.71 |
| Operating Expense | 183.95 | 192.93 | 188.54 | 181.77 |
| Operating Income | -18.22 | -18.68 | -33.84 | -24.06 |
| EBITDA | 11.13 | 12.19 | -6.13 | 1.74 |
| EBIT | -18.22 | -18.68 | -33.84 | -24.06 |
| Pretax Income | -29.95 | -54.44 | -191.64 | -34.03 |
| Tax Provision | -3.40 | -2 | -7.29 | -0.04 |
| Net Income | -26.55 | -52.44 | -184.35 | -33.99 |
| Net Income Common Stockholders | -26.55 | -52.44 | -184.35 | -33.99 |
| Total Expenses | 334.44 | 357.43 | 337.76 | 316.56 |
| Interest Expense | 0.69 | 2.70 | 0 | 0 |
| Research And Development | 30.74 | 29.88 | 31.51 | 26.22 |
| Selling General And Administration | 133.75 | 144.25 | 143.98 | 145.23 |
| Normalized EBITDA | 21.39 | 44.70 | 152.46 | 17.63 |
| Normalized Income | -17.46 | -21.13 | -31.78 | -18.12 |
| Basic EPS | -0.68 | -1.33 | -4.59 | -0.83 |
| Diluted EPS | -0.68 | -1.33 | -4.59 | -0.83 |
| Tax Effect Of Unusual Items | -1.16 | -1.19 | -6.03 | -0.02 |
| Tax Rate For Calcs | 0.11 | 0.04 | 0.04 | 0 |
| Total Unusual Items | -10.25 | -32.50 | -158.59 | -15.89 |
| Total Unusual Items Excluding Goodwill | -10.25 | -32.50 | -158.59 | -15.89 |
| Net Income From Continuing Operation Net Minority Interest | -26.55 | -52.44 | -184.35 | -33.99 |
| Reconciled Depreciation | 29.35 | 30.87 | 27.71 | 25.80 |
| Reconciled Cost Of Revenue | 140.60 | 152.42 | 134.55 | 119.31 |
| Net Interest Income | -0.69 | -2.70 | 1.61 | 0.98 |
| Net Income From Continuing And Discontinued Operation | -26.55 | -52.44 | -184.35 | -33.99 |
| Total Operating Income As Reported | -28.47 | -51.18 | -192.44 | -39.95 |
| Diluted Average Shares | 39.01 | 39.48 | 40.18 | 40.85 |
| Basic Average Shares | 39.01 | 39.48 | 40.18 | 40.85 |
| Diluted NI Availto Com Stockholders | -26.55 | -52.44 | -184.35 | -33.99 |
| Net Income Including Noncontrolling Interests | -26.55 | -52.44 | -184.35 | -33.99 |
| Net Income Discontinuous Operations | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | -26.55 | -52.44 | -184.35 | -33.99 |
| Other Income Expense | -11.04 | -33.06 | -159.41 | -10.95 |
| Other Non Operating Income Expenses | -0.79 | -0.55 | -0.82 | 4.94 |
| Special Income Charges | -10.25 | -32.50 | -158.59 | -15.89 |
| Gain On Sale Of Ppe | 0 | 0 | 54.50 | 0 |
| Gain On Sale Of Business | 0 | 0 | 0 | 0 |
| Other Special Charges | 7.62 | 10 | 34.94 | 0.71 |
| Impairment Of Capital Assets | 0 | 14.55 | 165.74 | 0 |
| Restructuring And Mergern Acquisition | 2.63 | 7.96 | 12.41 | 15.18 |
| Net Non Operating Interest Income Expense | -0.69 | -2.70 | 1.61 | 0.98 |
| Total Other Finance Cost | 0.69 | 2.70 | -1.61 | -0.98 |
| Interest Expense Non Operating | 0.69 | 2.70 | 0 | 0 |
| Depreciation Amortization Depletion Income Statement | 19.46 | 18.79 | 13.05 | 10.32 |
| Depreciation And Amortization In Income Statement | 19.46 | 18.79 | 13.05 | 10.32 |
| Amortization | 19.46 | 18.79 | 13.05 | 10.32 |
| Amortization Of Intangibles Income Statement | 19.46 | 18.79 | 13.05 | 10.32 |
| Selling And Marketing Expense | 95.30 | 104.25 | 102.82 | 103.14 |
| General And Administrative Expense | 38.45 | 40 | 41.16 | 42.09 |
| Other Gand A | 38.45 | 40 | 41.16 | 42.09 |
| Operating Revenue | 316.22 | 338.75 | 303.91 | 292.50 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| AngioDynamics, Inc.this co. | ANGO | $440M | - | 2.56 | -18.6% | -634.17 |
| Larimar Therapeutics, Inc. | LRMR | $451M | - | 4.62 | -212.2% | -1.85 |
| Perspective Therapeutics, Inc. | CATX | $448M | - | 1.41 | -49.8% | -2.78 |
| Myriad Genetics, Inc. | MYGN | $442M | - | 1.19 | -99.4% | -2.56 |
| Beta Bionics, Inc. | BBNX | $441M | - |
| 1.63 |
| -25.5% |
| -3.29 |
| Atea Pharmaceuticals, Inc. | AVIR | $435M | - | 1.54 | -57.5% | -0.73 |
| REGENXBIO Inc. | RGNX | $434M | - | 4.16 | -188.7% | -3.19 |
| Evolent Health, Inc. | EVH | $432M | - | 1.02 | -128.7% | 14.29 |
| Aura Biosciences, Inc. | AURA | $432M | - | 3.13 | -77.6% | -2.73 |
| Peer Median | - | - | 1.58 | -88.5% | -2.65 | |